Naosuke Yokomichi1, Naoshi Nishida2, Yuzo Umeda1, Fumitaka Taniguchi1, Kazuya Yasui1, Toshiaki Toshima1, Yoshiko Mori1, Akihiro Nyuya1,3, Takehiro Tanaka4, Takeshi Yamada5, Takahito Yagi1, Toshiyoshi Fujiwara1, Yoshiyuki Yamaguchi3, Ajay Goel6, Masatoshi Kudo2, Takeshi Nagasaka1,3. 1. Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. 2. Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan. 3. Department of Clinical Oncology, Kawasaki Medical School, Kurashiki, Japan. 4. Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. 5. Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Tokyo, Japan. 6. Center for Gastrointestinal Cancer Research, Center for Epigenetics, Cancer Prevention and Cancer Genomics, Baylor Research Institute and Charles A Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas, USA.
Abstract
OBJECTIVE: Keratin 19 (K19) expression is a potential predictor of poor prognosis in patients with hepatocellular carcinoma (HCC). To clarify the feature of K19-proficient HCC, we traced epigenetic footprints in cultured cells and clinical materials. PATIENTS AND METHODS: In vitro, KRT19 promoter methylation was analyzed and 5-aza-2'-deoxycytidine with trichostatin A (TSA) treatment was performed. Among 564 surgically resected HCCs, the clinicopathological relevance of K19-proficent HCCs was performed in comparison with hepatocytic (HepPar-1 and arginase-1), epithelial-mesenchymal transition (E-cadherin and vimentin), biliary differentiation-associated (K7 and NOTCH-1) markers, and epigenetic markers (KRT19 promoter/long interspersed nucleotide element-1 [LINE-1] methylation status). RESULTS: KRT19 promoter methylation was clearly associated with K19 deficiency and 5-aza-2'-deoxycytidine with TSA treatment-stimulated K19 re-expression, implicating DNA methylation as a potential epigenetic process for K19 expression. After excluding HCCs with recurrence, TNM stage as IIIB or greater, preoperative therapy, transplantation, and combined hepatocellular cholangiocarcinoma, we assessed 125 of 564 HCC cases. In this cohort, K19 expression was found in 29 HCCs (23.2%) and corresponded with poor survival following surgery (p = 0.025) and extrahepatic recurrence-free survival (p = 0.017). Compared with K19-deficient HCCs, lower KRT19 promoter methylation level was observed in K19-proficient HCCs (p < 0.0001). Conversely, HCC with genome-wide LINE-1 hypermethylation was frequently observed in K19-proficient HCCs (p = 0.0079). Additionally, K19 proficiency was associated with K7 proficiency (p = 0.043), and reduced E-cadherin and HepPar-1 expression (p = 0.043 and p < 0.0001, respectively). CONCLUSIONS: K19-proficient HCC exhibited poor prognosis owing to extrahepatic recurrence, with molecular signatures differing from those in conventional cancer stem cells, providing novel insights of the heterogeneity underlying tumor development.
OBJECTIVE: Keratin 19 (K19) expression is a potential predictor of poor prognosis in patients with hepatocellular carcinoma (HCC). To clarify the feature of K19-proficient HCC, we traced epigenetic footprints in cultured cells and clinical materials. PATIENTS AND METHODS: In vitro, KRT19 promoter methylation was analyzed and 5-aza-2'-deoxycytidine with trichostatin A (TSA) treatment was performed. Among 564 surgically resected HCCs, the clinicopathological relevance of K19-proficent HCCs was performed in comparison with hepatocytic (HepPar-1 and arginase-1), epithelial-mesenchymal transition (E-cadherin and vimentin), biliary differentiation-associated (K7 and NOTCH-1) markers, and epigenetic markers (KRT19 promoter/long interspersed nucleotide element-1 [LINE-1] methylation status). RESULTS: KRT19 promoter methylation was clearly associated with K19 deficiency and 5-aza-2'-deoxycytidine with TSA treatment-stimulated K19 re-expression, implicating DNA methylation as a potential epigenetic process for K19 expression. After excluding HCCs with recurrence, TNM stage as IIIB or greater, preoperative therapy, transplantation, and combined hepatocellular cholangiocarcinoma, we assessed 125 of 564 HCC cases. In this cohort, K19 expression was found in 29 HCCs (23.2%) and corresponded with poor survival following surgery (p = 0.025) and extrahepatic recurrence-free survival (p = 0.017). Compared with K19-deficient HCCs, lower KRT19 promoter methylation level was observed in K19-proficient HCCs (p < 0.0001). Conversely, HCC with genome-wide LINE-1 hypermethylation was frequently observed in K19-proficient HCCs (p = 0.0079). Additionally, K19 proficiency was associated with K7 proficiency (p = 0.043), and reduced E-cadherin and HepPar-1 expression (p = 0.043 and p < 0.0001, respectively). CONCLUSIONS: K19-proficient HCC exhibited poor prognosis owing to extrahepatic recurrence, with molecular signatures differing from those in conventional cancer stem cells, providing novel insights of the heterogeneity underlying tumor development.
Authors: Augusto Villanueva; Yujin Hoshida; Sara Toffanin; Anja Lachenmayer; Clara Alsinet; Radoslav Savic; Helena Cornella; Josep M Llovet Journal: Clin Cancer Res Date: 2010-08-16 Impact factor: 12.531
Authors: Benjamin C Yan; Can Gong; Jie Song; Thomas Krausz; Maria Tretiakova; Elizabeth Hyjek; Hikmat Al-Ahmadie; Venancio Alves; Shu-Yuan Xiao; Robert A Anders; John A Hart Journal: Am J Surg Pathol Date: 2010-08 Impact factor: 6.394
Authors: Michael C Zody; Manuel Garber; David J Adams; Ted Sharpe; Jennifer Harrow; James R Lupski; Christine Nicholson; Steven M Searle; Laurens Wilming; Sarah K Young; Amr Abouelleil; Nicole R Allen; Weimin Bi; Toby Bloom; Mark L Borowsky; Boris E Bugalter; Jonathan Butler; Jean L Chang; Chao-Kung Chen; April Cook; Benjamin Corum; Christina A Cuomo; Pieter J de Jong; David DeCaprio; Ken Dewar; Michael FitzGerald; James Gilbert; Richard Gibson; Sante Gnerre; Steven Goldstein; Darren V Grafham; Russell Grocock; Nabil Hafez; Daniel S Hagopian; Elizabeth Hart; Catherine Hosage Norman; Sean Humphray; David B Jaffe; Matt Jones; Michael Kamal; Varsha K Khodiyar; Kurt LaButti; Gavin Laird; Jessica Lehoczky; Xiaohong Liu; Tashi Lokyitsang; Jane Loveland; Annie Lui; Pendexter Macdonald; John E Major; Lucy Matthews; Evan Mauceli; Steven A McCarroll; Atanas H Mihalev; Jonathan Mudge; Cindy Nguyen; Robert Nicol; Sinéad B O'Leary; Kazutoyo Osoegawa; David C Schwartz; Charles Shaw-Smith; Pawel Stankiewicz; Charles Steward; David Swarbreck; Vijay Venkataraman; Charles A Whittaker; Xiaoping Yang; Andrew R Zimmer; Allan Bradley; Tim Hubbard; Bruce W Birren; Jane Rogers; Eric S Lander; Chad Nusbaum Journal: Nature Date: 2006-04-20 Impact factor: 49.962
Authors: Olivier Govaere; Mina Komuta; Johannes Berkers; Bart Spee; Carl Janssen; Francesca de Luca; Aezam Katoonizadeh; Jasper Wouters; Léon C van Kempen; Anne Durnez; Chris Verslype; Joery De Kock; Vera Rogiers; Leo A van Grunsven; Baki Topal; Jacques Pirenne; Hugo Vankelecom; Frederik Nevens; Joost van den Oord; Massimo Pinzani; Tania Roskams Journal: Gut Date: 2013-08-19 Impact factor: 23.059
Authors: Heba M I Abdallah; Sally A El Awdan; Rehab F Abdel-Rahman; Abdel Razik H Farrag; Rasha M Allam Journal: PLoS One Date: 2022-01-26 Impact factor: 3.240